Inventory

The major classes of inventory were as follows:



Inventory	September 30, 2015		December 31, 2014
	(in thousands)
Raw materials	$	39,719	$	40,533
Work-in-progress	58,620		34,095
Finished goods	15,926		6,822
Total	$	114,265	$	81,450

The Company reviews inventory, including inventory purchase commitments, for slow moving or obsolete amounts based on expected volume and provides reserves against the carrying amount of inventory as appropriate. During the three-month period ended September 30, 2015 upon review of expected future product sales volumes, the Company recorded a $16.7 million inventory obsolescence charge and a charge of $15.7 million for potential losses on future inventory purchase commitments due primarily to the loss of market exclusivity for Angiomax in the United States. For the nine-month period ended September 30, 2015, charges for inventory obsolescence and for potential losses on future inventory purchase commitments due primarily to the loss of market exclusivity for Angiomax in the United States total $25.1 million and $15.7 million, respectively.